BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...Hickey was SVP and chief commercial officer at Halozyme Therapeutics Inc (NASDAQ:HALO). Ocular cancer company Aura Biosciences Inc....
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

...Therapeutics GmbH (Hamburg, Germany); gastrointestinal company Phathom Pharmaceuticals LLC (Menlo Park, Calif.); ocular cancer play Aura Biosciences Inc....
BioCentury | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

...its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc....
...financing. Arix said it committed $4.5 million to increase its stake to 7.7%. Mark Zipkin, Staff Writer AU-011 Aura Biosciences Inc. Medicxi Melanoma...
BioCentury | Oct 5, 2018
Finance

Fruitful partnerships

...Autolus Therapeutics plc (NASDAQ:AUTL), T cell engaging company Harpoon Therapeutics Inc., directed viral nanoparticle company Aura Biosciences Inc....
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...Sept. 30. He will continue to serve on the inflammation company's board. Ocular cancer company Aura Biosciences Inc....
BioCentury | Dec 22, 2017
Financial News

Aura raises $30M series C

...molecules, and has Orphan Drug and Fast Track designations in the U.S. Aura Biosciences Inc., Cambridge, Mass. Chris Lieu AU-011 Aura Biosciences Inc....
BioCentury | Dec 21, 2017
Financial News

Aura raises $30M series C

...to infrared-activated small molecules, and has Orphan Drug and Fast Track designations in the U.S. Chris Lieu AU-011 Aura Biosciences Inc....
BioCentury | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

...acquired. She has served as CEO at PlaqueTec Ltd. (Cambridge, U.K.) since November. Cancer company Aura Biosciences Inc....
...Biosciences Inc. (Bedford, Mass.) hired Alison Lawton as president and COO. She was COO at Aura Biosciences Inc....
BioCentury | May 20, 2017
Strategy

Henri: N of 1

...developing them as treatments for refractory solid tumors. Termeer also invested in several biotechs, including Aura Biosciences Inc....
...Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Arrakis Therapeutics Inc., Waltham, Mass. Artax Biopharma Inc., Cambridge, Mass. Aura Biosciences Inc....
BioCentury | May 15, 2017
Company News

Orphan drug giant Termeer passes away

...Cambridge, Mass.), ProQR Therapeutics N.V. (NASDAQ:PRQR) and X4 Pharmaceuticals Inc. (Cambridge, Mass.); an investor in Aura Biosciences Inc....
Items per page:
1 - 10 of 23
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...Hickey was SVP and chief commercial officer at Halozyme Therapeutics Inc (NASDAQ:HALO). Ocular cancer company Aura Biosciences Inc....
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

...Therapeutics GmbH (Hamburg, Germany); gastrointestinal company Phathom Pharmaceuticals LLC (Menlo Park, Calif.); ocular cancer play Aura Biosciences Inc....
BioCentury | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

...its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc....
...financing. Arix said it committed $4.5 million to increase its stake to 7.7%. Mark Zipkin, Staff Writer AU-011 Aura Biosciences Inc. Medicxi Melanoma...
BioCentury | Oct 5, 2018
Finance

Fruitful partnerships

...Autolus Therapeutics plc (NASDAQ:AUTL), T cell engaging company Harpoon Therapeutics Inc., directed viral nanoparticle company Aura Biosciences Inc....
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...Sept. 30. He will continue to serve on the inflammation company's board. Ocular cancer company Aura Biosciences Inc....
BioCentury | Dec 22, 2017
Financial News

Aura raises $30M series C

...molecules, and has Orphan Drug and Fast Track designations in the U.S. Aura Biosciences Inc., Cambridge, Mass. Chris Lieu AU-011 Aura Biosciences Inc....
BioCentury | Dec 21, 2017
Financial News

Aura raises $30M series C

...to infrared-activated small molecules, and has Orphan Drug and Fast Track designations in the U.S. Chris Lieu AU-011 Aura Biosciences Inc....
BioCentury | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

...acquired. She has served as CEO at PlaqueTec Ltd. (Cambridge, U.K.) since November. Cancer company Aura Biosciences Inc....
...Biosciences Inc. (Bedford, Mass.) hired Alison Lawton as president and COO. She was COO at Aura Biosciences Inc....
BioCentury | May 20, 2017
Strategy

Henri: N of 1

...developing them as treatments for refractory solid tumors. Termeer also invested in several biotechs, including Aura Biosciences Inc....
...Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Arrakis Therapeutics Inc., Waltham, Mass. Artax Biopharma Inc., Cambridge, Mass. Aura Biosciences Inc....
BioCentury | May 15, 2017
Company News

Orphan drug giant Termeer passes away

...Cambridge, Mass.), ProQR Therapeutics N.V. (NASDAQ:PRQR) and X4 Pharmaceuticals Inc. (Cambridge, Mass.); an investor in Aura Biosciences Inc....
Items per page:
1 - 10 of 23